BioRegenx, Inc. (BRGX)
| Market Cap | 8.72M |
| Revenue (ttm) | 1.85M |
| Net Income (ttm) | -1.54M |
| Shares Out | 969.02M |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 543 |
| Average Volume | 76,679 |
| Open | 0.0090 |
| Previous Close | 0.0090 |
| Day's Range | 0.0090 - 0.0090 |
| 52-Week Range | 0.0075 - 0.0300 |
| Beta | -2.87 |
| RSI | 41.72 |
| Earnings Date | May 14, 2026 |
About BioRegenx
BioRegenx, Inc. develops, manufactures, and sells medical test equipment and science-based nutritional products in the United States and internationally. The company offers Endocalyx Pro, a dietary supplement targeting microvascular capillary health and a range of other supplements under the MyBodyRx brand name; GlycoCheck software; and other health and wellness devices, such as pulsed electro-magnetic field devices, as well as StimaWELL and ReLounge, an electronic muscle stimulation therapy device; and markets hydrogen water products. It also ... [Read more]
Financial Performance
In 2025, BioRegenx's revenue was $1.85 million, a decrease of -20.75% compared to the previous year's $2.34 million. Losses were -$1.54 million, -93.30% less than in 2024.
Financial StatementsNews
BioRegenx, Inc. Engages Sichenzia Ross Ference Carmel LLP for Legal Representation in Connection with Planned Uplisting to National Stock Exchange
CHATTANOOGA, TENNESSEE / ACCESS Newswire / May 13, 2025 / BioRegenx, Inc. ("BioRegenx" or the "Company") (OTC Pink:BRGX), a health technology company advancing microvascular and metabolic health throu...